Additionally, targeting signalling of CCL2/CCR2 with a CCR2 antagonist was found to remarkably reduce TAM recruitment and polarization, thus enhancing the immunotherapeutic effect of tumour.42 This evidence concerns the gene CCL2 and neoplasm.